JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spicer, S. S.
Right arrow Articles by Monaco, A. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Spicer, S. S.
Right arrow Articles by Monaco, A. R.
Journal of Pharmacology And Experimental Therapeutics, Vol. 95, Issue 2, 256-261, 1949
Copyright © 1949 by American Society for Pharmacology and Experimental Therapeutics

TOXIC AND PATHOLOGIC EFFECTS OF XYLIDINE IN THE FASTING AND NON-FASTING STATES

Samuel S. Spicer 1, Benjamin Highman 1, and A. Ralph Monaco 1

1 Experimental Biology & Medicine Institute, Laboratory of Physical Biology, and Pathology Laboratory, National Institutes of Health, Bethesda, Maryland

In contrast to fasted cats, those fed milk or milk and yeast reacted to xylidine vapors with an acute disturbance characterized by hyperpnea, panting, ptyalism, and frequently early death. Survivors of both groups developed a high level of MHb and Heinz bodies in the blood, often followed by a severe hemolytic anemia and jaundice.

Pathologic studies showed pulmonary edema occurring chiefly in the hyperpneic animals and lesions of the liver, kidney, heart and thymus occurring in both groups.

Submitted on November 3, 1948






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1949 by the American Society for Pharmacology and Experimental Therapeutics.